MY177001A - Phenothiazine compounds for treating mild cognitive impairment - Google Patents

Phenothiazine compounds for treating mild cognitive impairment

Info

Publication number
MY177001A
MY177001A MYPI20095255A MYPI20095255A MY177001A MY 177001 A MY177001 A MY 177001A MY PI20095255 A MYPI20095255 A MY PI20095255A MY PI20095255 A MYPI20095255 A MY PI20095255A MY 177001 A MY177001 A MY 177001A
Authority
MY
Malaysia
Prior art keywords
cognitive impairment
mild cognitive
treating mild
phenothiazine compounds
phenothiazine
Prior art date
Application number
MYPI20095255A
Other languages
English (en)
Inventor
Claude Michel Wischik
Gernot Riedel
Dominic Venay Harbaran
Serena Deiana
Damon Jude Wischik
Roger Todd Staff
Elizabeth Anne Goatman
Alison Dorothy Murray
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of MY177001A publication Critical patent/MY177001A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20095255A 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment MY177001A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94500607P 2007-06-19 2007-06-19
PCT/GB2008/002066 WO2008155533A2 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Publications (1)

Publication Number Publication Date
MY177001A true MY177001A (en) 2020-09-01

Family

ID=39943003

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20095255A MY177001A (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Country Status (16)

Country Link
US (1) US9211294B2 (enExample)
EP (1) EP2167095B1 (enExample)
JP (1) JP5725605B2 (enExample)
CN (1) CN101820884B (enExample)
AU (1) AU2008265045B2 (enExample)
BR (1) BRPI0813670A2 (enExample)
CA (1) CA2690746C (enExample)
DK (1) DK2167095T3 (enExample)
ES (1) ES2739546T3 (enExample)
HR (1) HRP20191513T1 (enExample)
HU (1) HUE045460T2 (enExample)
MY (1) MY177001A (enExample)
PL (1) PL2167095T3 (enExample)
PT (1) PT2167095T (enExample)
SI (1) SI2167095T1 (enExample)
WO (1) WO2008155533A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
CA2701075C (en) * 2007-10-03 2019-02-12 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines.
JP5868955B2 (ja) 2010-04-30 2016-02-24 プロセッタ アンチバイラル インコーポレイテッド 抗ウイルス化合物
JP5898701B2 (ja) * 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
EP2699241B1 (en) 2011-04-20 2016-07-27 Prosetta Antiviral Inc. Antiviral compounds
US9523045B2 (en) * 2013-01-30 2016-12-20 Ecolab Usa Inc. Hydrogen sulfide scavengers
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
US10472340B2 (en) * 2015-02-17 2019-11-12 Arizona Board Of Regents On Behalf Of Arizona State University Substituted phenothiazines as mitochondrial agents
JP7073330B2 (ja) * 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
FI4385512T3 (fi) 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909454D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
AU2023279800A1 (en) 2022-05-31 2024-12-19 TauRx Therapeutics Management Ltd Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
KR20250154422A (ko) 2023-03-03 2025-10-28 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 미세혈관 뇌질환 치료를 위한 디아미노페노티아진

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
EP1617844A4 (en) * 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
CN101084204B (zh) * 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
SI2322517T1 (sl) * 2004-09-23 2019-06-28 Wista Laboratories Ltd. Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC)
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
SI2004155T1 (en) * 2006-03-29 2018-05-31 Wista Laboratories Ltd. Inhibitors of protein aggregation
ES2349322T7 (es) * 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
WO2007110630A1 (en) * 2006-03-29 2007-10-04 Wista Laboratories Ltd. Thioninium compounds and their use
MY148145A (en) * 2006-07-11 2013-03-15 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds

Also Published As

Publication number Publication date
JP5725605B2 (ja) 2015-05-27
EP2167095B1 (en) 2019-05-29
AU2008265045A1 (en) 2008-12-24
CA2690746C (en) 2018-01-02
US20100184752A1 (en) 2010-07-22
JP2010530403A (ja) 2010-09-09
DK2167095T3 (da) 2019-07-29
SI2167095T1 (sl) 2019-09-30
CA2690746A1 (en) 2008-12-24
PT2167095T (pt) 2019-08-06
CN101820884B (zh) 2013-08-28
BRPI0813670A2 (pt) 2014-12-30
HRP20191513T1 (hr) 2019-11-29
US9211294B2 (en) 2015-12-15
PL2167095T3 (pl) 2019-11-29
AU2008265045B2 (en) 2014-02-27
HUE045460T2 (hu) 2019-12-30
ES2739546T3 (es) 2020-01-31
WO2008155533A3 (en) 2009-02-19
EP2167095A2 (en) 2010-03-31
CN101820884A (zh) 2010-09-01
WO2008155533A2 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
MY177001A (en) Phenothiazine compounds for treating mild cognitive impairment
NL301145I1 (enExample)
MX2010006823A (es) Metodos para el tratamiento de la gota.
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
MX2022009759A (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea.
TW200716624A (en) Compounds for modulating TRPV3 function
MX2007016322A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
WO2010036395A3 (en) Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
MY147247A (en) Organic compounds and their uses
EP1924293A4 (en) COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF DIABETES TYPE I
ZA201002764B (en) Benzodiazepinone compounds useful in the treatment of skin conditions
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
MX2010002909A (es) Metodo de tratamiento de pacientes de hepatitis c.
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MY155340A (en) Use of cathepsin c
TW200716088A (en) Formulations and methods for treating amyloidosis
MX2009013214A (es) Macrociclos y sus usos.
TW200716015A (en) Methods and apparatuses for sealing ophthalmic lens packages